| 刘 悦,王 力,王 超,刘晶晶,刘广志.不同剂量阿托伐他汀联合依达拉奉对急性脑梗死患者血脂、炎症因子和脑血流指标的影响[J].现代生物医学进展英文版,2021,(20):3871-3875. |
| 不同剂量阿托伐他汀联合依达拉奉对急性脑梗死患者血脂、炎症因子和脑血流指标的影响 |
| Effects of Different Doses of Atorvastatin Combined with Edaravone on Blood Lipid, Inflammatory Factors and Cerebral Blood Flow Indexes in Patients with Acute Cerebral Infarction |
| Received:April 28, 2021 Revised:May 23, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.20.014 |
| 中文关键词: 阿托伐他汀 依达拉奉 急性脑梗死 血脂 炎症因子 脑血流指标 |
| 英文关键词: Atorvastatin Edaravone Acute cerebral infarction Blood lipid Inflammatory factors Cerebral blood flow index |
| 基金项目:北京市科学技术委员会基金项目（z151100003915134） |
|
| Hits: 979 |
| Download times: 640 |
| 中文摘要: |
| 摘要 目的：探讨依达拉奉分别联合不同剂量的阿托伐他汀对急性脑梗死（ACI）患者血脂、炎症因子和脑血流指标的影响。方法：纳入2018年3月~2020年1月期间我院收治的81例ACI患者，采用随机数字表法分为低剂量组（依达拉奉联合10 mg/d阿托伐他汀治疗）、中剂量组（依达拉奉联合20 mg/d阿托伐他汀治疗）和高剂量组（依达拉奉联合40 mg/d阿托伐他汀治疗），每组各27例。对比三组疗效、血脂、炎症因子、脑血流指标、相关量表评分及不良反应。结果：治疗14 d后，高剂量组、中剂量组总有效率高于低剂量组，且高剂量组高于中剂量组（P<0.05）。治疗14 d后，高剂量组、中剂量组美国国立卫生研究院卒中量表（NIHSS）、改良Rankin 量表（mRS）评分和总胆固醇 (TC ) 、三酰甘油 (TG )、低密度脂蛋白胆固醇 (LDL-C )、超敏C反应蛋白（hs-CRP）、白介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）低于低剂量组，且高剂量组低于中剂量组（P<0.05）。治疗14 d后，高剂量组、中剂量组高密度脂蛋白胆固醇 (HDL-C )高于低剂量组，且高剂量组高于中剂量组（P<0.05）。治疗14 d后，三组平均血流速度较治疗前增加，外周阻力较治疗前降低（P<0.05），但三组间平均血流速度和外周阻力比较差异无统计学意义（P>0.05）。三组不良反应发生率组间对比差异无统计学意义（P>0.05）。结论：40 mg/d阿托伐他汀联合依达拉奉治疗ACI患者，可更加有效控制疾病进展，改善机体血脂、炎症因子，较为安全可靠，但有关脑血流的改变可能与阿托伐他汀剂量无关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of edaravone combined with different doses of atorvastatin on blood lipid, inflammatory factors and cerebral blood flow in patients with acute cerebral infarction(ACI). Methods: A total of 81 patients with ACI in our hospital from March 2018 to January 2020 were selected, and they were randomly divided into low-dose group (edaravone combined with 10 mg/d atorvastatin), medium-dose group (edaravone combined with 20 mg/d atorvastatin) and high-dose group (edaravone combined with 40 mg/d atorvastatin), with 27 cases in each group. The curative effect, blood lipid, inflammatory factors, cerebral blood flow indexes, related scale score and adverse reactions of the three groups were compared. Results: 14 d after treatment, the total effective rate of high-dose group and medium-dose group was higher than that of low-dose group, and the high-dose group was higher than that of medium dose group(P<0.05). 14 d after treatment, the scores of National Institutes of Health Stroke Scale(NIHSS), modified Rankin Scale (mRS) scores and total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), hypersensitive C-reactive protein (hs-CRP), interleukin-8 (IL-8), tumor necrosis factor-α(TNF-α) of high-dose group and medium-dose group were lower than those of low-dose group, and the high-dose group was lower than the medium-dose group (P<0.05). 14 d after treatment, the high-density lipoprotein cholesterol(HDL-C) of high-dose group and medium-dose group was higher than that of low-dose group, and high-dose group was higher than the medium-dose group(P<0.05). 14 d after treatment, the mean blood flow velocity of the three groups was increased compared with that before treatment, peripheral resistance was lower than that before treatment(P<0.05), but there were no significant differences in the mean blood flow velocity and peripheral resistance among the three groups(P>0.05). There was no significant difference in the incidence of adverse reactions among the three groups (P>0.05). Conclusion: 40 mg/d Atorvastatin combined with edaravone in the treatment of ACI patients can more effectively control the disease progression, improve the body's blood lipid and inflammatory factors, which is more safe and reliable, but the changes of cerebral blood flow may not be related to the dose of atorvastatin. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
